Last reviewed · How we verify
Floxin (OFLOXACIN)
Floxin (Ofloxacin) is a quinolone antimicrobial drug developed by Hoechst Marion Roussel, currently owned by Daiichi. It targets bacterial DNA replication by inhibiting the enzyme DNA gyrase, leading to bacterial cell death. Floxin is approved to treat various bacterial infections, including respiratory, urinary, and skin infections. The drug is available as a generic medication, with over 20 manufacturers, and is no longer protected by patents. Key safety considerations include potential central nervous system effects, such as dizziness and confusion, and the risk of tendon rupture.
At a glance
| Generic name | OFLOXACIN |
|---|---|
| Sponsor | Daiichi |
| Drug class | Quinolone Antimicrobial [EPC] |
| Target | Histamine H3 receptor |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1990 |
Approved indications
- Abdominal abscess
- Acute Moraxella catarrhalis bronchitis
- Acute bacterial bronchitis
- Acute bacterial peritonitis
- Acute bacterial sinusitis
- Acute exacerbation of chronic bronchitis
- Acute gonococcal cervicitis
- Acute gonococcal endometritis
- Acute gonococcal urethritis
- Acute maxillary sinusitis
- Acute osteomyelitis
- Anthrax
- Bacterial Corneal Ulcer Infection
- Bacterial conjunctivitis
- Bacterial infection due to Klebsiella pneumoniae
- Bacterial pneumonia
- Bacterial urinary infection
- Bronchitis
- Chancroid
- Chlamydia Cervicitis
Common side effects
- Application Site Reaction
- Taste Perversion
- Pruritus
- Earache
- Dizziness
- Paraesthesia
- Rash
- Headache
- Vertigo
- Nausea
- Seborrhea
- Transient loss of hearing
Drug interactions
- High Risk QT Prolonging Agents
- dronedarone
- prednisolone
- prednisone
- sucralfate
- tizanidine
- tolbutamide
- warfarin
Key clinical trials
- Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (PHASE2,PHASE3)
- Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding" (PHASE3)
- Antibiotyping and Prevalence of Virulent Genotypes Among Helicobacter Pylori and Their Impact on Response to Therapy (NA)
- Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (NA)
- Antibiotics vs Corticosteroids in Treatment of Granulomatous Lobular Mastitis (PHASE1,PHASE2)
- Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1,PHASE2)
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Floxin CI brief — competitive landscape report
- Floxin updates RSS · CI watch RSS